Novo Nordisk Ignored Internal Warnings On Wegovy Launch Preparedness: Report

Novo Nordisk A/S’ (NYSE:NVO) executives allegedly ignored internal warnings that the company was unprepared to launch its obesity drug Wegovy.

As rival Eli Lilly and Co.’s (NYSE:LLY) Zepbound gains momentum, the Danish pharmaceutical giant is grappling with the fallout of those early decisions.

Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.

Also Read: Spain Accuses Novo Nordisk Of Covert Advertising For Prescription Weight-Loss Drugs

But the company has struggled to keep pace with Lilly’s Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.

Amid concerns over its competitiveness in the weight-loss market, Novo is undergoing a leadership shake-up, including